CYCCP - Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024 | Benzinga
BERKELEY HEIGHTS, N.J., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that Spiro Rombotis, President & Chief Executive Officer, will present an overview of its business and provide updates on its clinical programs at Biotech Showcase, taking place January 8-10, 2024 in San Francisco, California.
Details of Cyclacel's corporate update presentation are as follows:
Date: Monday, January 8, 2024
Time: 11:00AM PT
Location: Hilton San Francisco – Union Square, San Francisco, CA
Track: Yosemite C (Ballroom Level)
About Cyclacel Pharmaceuticals, Inc.
Cyclacel is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation, epigenetics and mitosis biology. The transcriptional regulation program is evaluating fadraciclib, a CDK2/9 inhibitor, and the epigenetic/anti-mitotic program plogosertib, a PLK1 inhibitor, in patients with both solid tumors and hematological malignancies. Cyclacel's strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications. For additional information, please visit www.cyclacel.com.
Forward-looking ...